Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BIVI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
globenewswire.com
20 hours ago
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-2.30
vs -3.30
Q3.23
N/A
-2.90
vs -3.80
Q4.23
N/A
-2.20
vs -5.00
Q1.24
N/A
-2.00
vs -4.30
Q2.24
N/A
-6.60
vs -2.30
Q3.24
N/A
-0.70
vs -2.90
Q4.24
N/A
-0.46
vs -2.20
Q1.25
N/A
-1.50
vs -2.00
Q2.25
N/A
-3.60
vs -6.60
Q3.25
N/A
-4.40
vs -0.70
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q4.22
-60%
-0.60
vs -1.75
Q1.23
-69%
-0.69
vs -0.60
Q2.23
-59%
-0.59
vs -0.69
Q3.23
-142%
-1.42
vs -0.59
Q4.23
-112%
-1.12
vs -1.42
Q1.24
-47%
-0.47
vs -1.12
Q2.24
-32%
-0.32
vs -0.47
Q3.24
-30%
-0.30
vs -0.32
Q4.24
-30%
-0.30
vs -0.30
Q1.25
-13%
-0.13
vs -0.30
Institutionnal Ownership
QoQ
Q4.22
38
38
vs 17
124%
Q1.23
53
53
vs 38
39%
Q2.23
57
57
vs 53
8%
Q3.23
65
65
vs 57
14%
Q4.23
61
61
vs 65
-6%
Q1.24
52
52
vs 61
-15%
Q2.24
50
50
vs 52
-4%
Q3.24
27
27
vs 50
-46%
Q4.24
43
43
vs 27
59%
Q1.25
37
37
vs 43
-14%
Quote Panel
Key Metrics
Forecast
2026-Revenue
-907%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
ThinkEquity
initialisePrevious: Not converted
2024-07-01
Now: Buy
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
NASDAQ
Unprofitable
Unprofitable
0.10 ( 6.06%)
Relative Strenght
84
Volume Buzz
101%
Earning Acce
Yes
Dist 52w H.
98%Relative Strength
BIVI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|